0.00
전일 마감가:
$135.07
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$10.20B
수익:
-
순이익/손실:
$-274.62M
주가수익비율:
0.00
EPS:
-4.3278
순현금흐름:
$-235.37M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
APGE
Apogee Therapeutics Inc
|
0.00 | 10.20B | 0 | -274.62M | -235.37M | -4.3278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Hold |
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
APOE THERPAR: Shareholders Board Members Managers and Company Profile | US03770N1019 - marketscreener.com
Fairmount Funds Management LLC Exits Apogee Therapeutics Inc (AP - GuruFocus
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - AD HOC NEWS
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Fairmount Funds Management Exits Apogee Therapeutics (NASDAQ: APGE) Following $135.11 Per Share Merger Payout - Kalkine Media
Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting - theglobeandmail.com
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
Apogee Therapeutics (APGE) director-linked funds fully exit in AbbVie deal - Stock Titan
Apogee Therapeutics (APGE) CMO cashes out stock and options in AbbVie deal - Stock Titan
Apogee (APGE) director’s shares and options cashed out in AbbVie deal - Stock Titan
Apogee merger pays $135.11 per share in cash | APGE SEC FilingForm SCHEDULE 13D/A - Stock Titan
AbbVie Completes $10.9 Billion Acquisition Of Apogee Therapeutics - Pulse 2.0
AbbVie (ABBV) Completes Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Finalizes $10.9 Billion Acquisition of Apogee Therapeutics, Initiates Nasdaq Delisting - Kalkine Media
Biotech Stocks To Follow NowSeptember 3rd - MarketBeat
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline - dermatologytimes.com
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
Apogee Therapeutics (Nasdaq: APGE) loses its Nasdaq listing - Stock Titan
ABBV Looks 19.1% Overvalued on GF Value™ Amid $10.9B Apogee Acqu - GuruFocus
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - Seeking Alpha
Apogee Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
AbbVie’s $10.9 billion deal adds a late-stage eczema treatment - Stock Titan
Director cashes out Apogee (NASDAQ: APGE) stake in AbbVie merger - Stock Titan
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from S&P Global BMI Index - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from S&P TMI Index - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from NASDAQ Composite Index - marketscreener.com
APGE Stock Price, Quote & Chart - ChartMill
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Apogee Therapeutics stock hits all-time high at 134.89 USD - Investing.com
Apogee Therapeutics Market Sentiment - Benzinga España
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - news.stocktradersdaily.com
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Apogee Therapeutics Inc 주식 (APGE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Aug 05 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
173,998 |
| Dambkowski Carl | Chief Medical Officer |
Aug 05 '26 |
Sale |
134.17 |
5,500 |
737,935 |
168,498 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Jul 08 '26 |
Sale |
133.63 |
20,000 |
2,672,600 |
995,987 |
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
183,373 |
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Sale |
132.74 |
5,500 |
730,070 |
177,873 |
자본화:
|
볼륨(24시간):